Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.

International journal of cancer - 1 Jul 2007

Müller Christoph R, Paulsen Erik B, Noordhuis Paul, Pedeutour Florence, Saeter Gunnar, Myklebost Ola

Abstract excerpt

The MDM2-antagonist Nutlin 3A can efficiently induce apoptosis in osteosarcoma cell lines with amplified MDM2. However, Nutlin-based therapy could be even more important in more common sarcoma types where this aberration is frequent. The well- and de-differentiated liposarcomas have complex marker chromosomes, consistently including multiple copies of the MDM2 locus. Since amplification seems to be a primary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Cell Line, Tumor
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liposarcoma

Share to Piperazines

Share to Proto-Oncogene Proteins c-mdm2

Share to Sensitivity and Specificity

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 17354236
DOI: 10.1002/ijc.22643

Genes

MDM2
MDM4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.PMID 17354236Read ↗

In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas.Semantic proximity Read ↗

Gene Expression Profiling of Liposarcoma Identifies Distinct Biological Types/Subtypes and Potential Therapeutic Targets in Well-Differentiated and Dedifferentiated LiposarcomaSemantic proximity Read ↗

MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of actionSemantic proximity Read ↗

Clinical and Molecular Spectrum of LiposarcomaSemantic proximity Read ↗

Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response PathwaySemantic proximity Read ↗

Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.Semantic proximity Read ↗

Targeting the MDM2-p53 pathway in dedifferentiated liposarcomaSemantic proximity Read ↗

SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated LiposarcomaSemantic proximity Read ↗

Nutlin-3a Is a Potential Therapeutic for Ewing SarcomaSemantic proximity Read ↗

Liposarcoma: Molecular Genetics and TherapeuticsSemantic proximity Read ↗

MDM2 inhibitors in sarcomas: results and next stepsSemantic proximity Read ↗

MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.